Kalaris Therapeutics, Inc.
KLRS
$4.90
-$0.32-6.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.80% | -5.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.23% | 3.96% | |||
| Operating Income | 15.23% | -3.96% | |||
| Income Before Tax | 15.94% | -4.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.94% | -4.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.94% | -4.79% | |||
| EBIT | 15.23% | -3.96% | |||
| EBITDA | 15.30% | -- | |||
| EPS Basic | 19.20% | -4.79% | |||
| Normalized Basic EPS | 19.19% | -4.80% | |||
| EPS Diluted | 19.20% | -4.79% | |||
| Normalized Diluted EPS | 19.19% | -4.80% | |||
| Average Basic Shares Outstanding | 4.02% | 0.00% | |||
| Average Diluted Shares Outstanding | 4.02% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||